Conclusions
Based on the results of this post hoc analysis in participants from phase 3 of MOVe-OUT, the use of molnupiravir appears to be effective and safe for the treatment of mild-to-moderate COVID-19 in non-hospitalized immunocompromised adults at risk for progression to severe COVID-19. There were no notable differences in virologic outcomes among molnupiravir-treated participants based on immunocompromised status, further corroborating the clinical findings in immunocompromised participants. NGS analyses taken together with infectivity data suggest that immunocompromised individuals are not more likely to develop amino acid substitutions, thereby minimizing the possibility for the development of novel SARS-CoV-2 variants following treatment with molnupiravir.